|Description||LY3130481, a benzothiazol derivative, has been found to be the first AMPA receptor antagonist that could be probably effective in studies of epilepsy. It has just been planed a Phase I trial by Cerecor.|
|Synonyms||LY3130481; LY-3130481; LY 3130481; CERC-611; CERC611; CERC 611. (S)-6-(1-(1-(5-(2-hydroxyethoxy)pyridin-2-yl)-1H-pyrazol-3-yl)ethyl)benzo[d]thiazol-2(3H)-one|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
CP 465022, with anticonvulsant activity, is a potent, brain penetrant, orally active and selective noncompetitive AMPA receptor antagonist (IC50 = 25 nM in rat ...
GYKI 53655 is a selective AMPA receptor antagonist with anticonvulsant activity.
Tezampanel, a decahydroisoquinoline derivative, has been found to be AMPA receptor as well as Kainic acid receptor antagonist that could probably be useful in s...
NBQX disodium salt
The sodium salt form of NBQX, which has been found to be an AMPA receptor antagonist and could be used as neuroprotective as well as anticonvulsant agent.
Cyclothiazide has been found to be a subunit-specific inhibitor of GABAC receptors and could be used as a diuretic agent as well as antihypertensive agent.
Aniracetam is a nootropics and neuroprotective drug.
GYKI-53405 is a noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA receptor) antagonist. It can bind to Xenopus brain membranes ...
(RS)-AMPA has been found to be a definitive agonist of the AMPA glutamatergic ionotropic receptor.